Protocols
ABBVIE-M22-947 Phase I OPEN TO ACCRUAL
A Dose Escalation and Expansion Study of AbbVie's Compound in Combination with Anti-Cancer Myeloma Regimens for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma
BEIGENE-BGB-11417-105 Phase I/II OPEN TO ACCRUAL
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination with Dexamethasone and Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and t(11;14)
C4THERAPEUTICS-CFT7455-1101 Phase I/II OPEN TO ACCRUAL
A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects with Relapsed/Refractory Non-Hodgkin Lymphoma or Multiple Myeloma
COLUMBIAUNIVERSITY-AAAT8639 Phase I/II OPEN TO ACCRUAL
An Open-label Phase I/II Trial of Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Systemic Light-Chain Amyloidosis
FATE-FT576-101-MM Phase I OPEN TO ACCRUAL
A Phase I Study of FT576 as Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma
ICHNOS-ISB-1442-101 Phase I/II OPEN TO ACCRUAL
A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma
IIT-DHAKAL-IMPEDE-SGZ-12356 Phase II OPEN TO ACCRUAL
A Multisite, Phase II Study of Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
IIT-DHAKAL-VICD-MM Phase II OPEN TO ACCRUAL
A Multisite, Phase II Study of Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone (VICD) Induction in Transplant-Eligible Multiple Myeloma Patients with or without Renal Insufficiency
IIT-MOHAN-E-MAT Phase II OPEN TO ACCRUAL
Combination Post-Transplant Consolidation Therapy with Isatuximab, Lenalidomide, Dexamethasone (IsaRD) in Multiple Myeloma Patients with Persistent Marrow Minimal Residual Disease (Elimination of MRD After Transplant; E-MAT)
JNJ-MY4002-CARTINUE-LTFU Phase IV OPEN TO ACCRUAL
Long-Term Follow-Up Study for Participants Previously Treated with Ciltacabtagene Autoleucel
PROTHENA-NEOD001-301 Phase III OPEN TO ACCRUAL
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis
SWOG-S1803-CTN-1706-DRAMMATIC Phase III OPEN TO ACCRUAL
Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
WEILLCORNELL-AMY2006-DPD Phase II OPEN TO ACCRUAL
Daratumumab, Pomalidomide and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab